1
|
Li W, Wan P, Qiao J, Liu Y, Peng Q, Zhang Z, Shu X, Xia Y, Sun B. Current and further outlook on the protective potential of Antrodia camphorata against neurological disorders. Front Pharmacol 2024; 15:1372110. [PMID: 38694913 PMCID: PMC11061445 DOI: 10.3389/fphar.2024.1372110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2024] [Accepted: 04/02/2024] [Indexed: 05/04/2024] Open
Abstract
Prevalent neurological disorders such as Alzheimer's disease, Parkinson's disease, and stroke are increasingly becoming a global burden as society ages. It is well-known that degeneration and loss of neurons are the fundamental underlying processes, but there are still no effective therapies for these neurological diseases. In recent years, plenty of studies have focused on the pharmacology and feasibility of natural products as new strategies for the development of drugs that target neurological disorders. Antrodia camphorata has become one of the most promising candidates, and the crude extracts and some active metabolites of it have been reported to play various pharmacological activities to alleviate neurological symptoms at cellular and molecular levels. This review highlights the current evidence of Antrodia camphorata against neurological disorders, including safety evaluation, metabolism, blood-brain barrier penetration, neuroprotective activities, and the potential on regulating the gut-microbiome-brain axis. Furthermore, potential strategies to resolve problematic issues identified in previous studies are also discussed. We aim to provide an overview for the ongoing development and utilization of Antrodia camphorata in cerebral neuropathology.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Yiyuan Xia
- Hubei Key Laboratory of Cognitive and Affective Disorders, Wuhan Institute of Biomedical Sciences, School of Medicine, Jianghan University, Wuhan, China
| | - Binlian Sun
- Hubei Key Laboratory of Cognitive and Affective Disorders, Wuhan Institute of Biomedical Sciences, School of Medicine, Jianghan University, Wuhan, China
| |
Collapse
|
2
|
Xu S, Yang J, Wan H, Yu L, He Y. Combination of Radix Astragali and Safflower Promotes Angiogenesis in Rats with Ischemic Stroke via Silencing PTGS2. Int J Mol Sci 2023; 24:ijms24032126. [PMID: 36768450 PMCID: PMC9916507 DOI: 10.3390/ijms24032126] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2022] [Revised: 01/13/2023] [Accepted: 01/17/2023] [Indexed: 01/25/2023] Open
Abstract
Promotion of angiogenesis and restoration of the blood flow in the ischemic penumbra is an effective treatment for patients with ischemic stroke (IS). Radix astragali-safflower (AS), a classic herbal pair for accelerating blood circulation and dispersing blood stasis, has been used for thousands of years to treat patients with IS in China. Even so, the mechanism of the treatment of IS by AS is still undecipherable. In the current study, network pharmacology was firstly employed to unveil the mechanism of AS in treating IS, which showed that AS might promote angiogenesis associated with PTGS2 silence. Middle cerebral artery occlusion/reperfusion (MCAO/R) model rats were then used as the experimental animals to verify the prediction result. The experimental results revealed that treatment with AS improved the cerebral infarct volume, neurological damage, and cerebral histopathological damage; inhibited cell apoptosis; increased the contents of PDGF-BB, EPO, and TGF-β1; and reduced the levels of PF4, Ang-2, and TIMP-1 in serum. Immunohistochemical staining demonstrated that the expression of PTGS2 was dramatically increased in the hippocampus and cerebral cortex of rats with MCAO/R, and this trend was reversed by the treatment of AS. Immunofluorescent staining expressed that AS reversed the down-regulation of VEGF and further promoted the expression of CD31, which indicated that AS promoted angiogenesis in MCAO/R rats. The abnormal protein or mRNA expression of PTGS2, PGI2, bFGF, TSP-1, and VEGF in the penumbra were transposed by AS or Celecoxib (an inhibitor of PTGS2). In conclusion, the protective mechanism of AS for IS promoted angiogenesis and was involved with PTGS2 silence.
Collapse
Affiliation(s)
- Shouchao Xu
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China
| | - Jiehong Yang
- School of Basic Medicine Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China
| | - Haitong Wan
- School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China
| | - Li Yu
- School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China
| | - Yu He
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China
- Correspondence: ; Tel.: +86-18858286825; Fax: +86-0571-61768136
| |
Collapse
|
3
|
Parvatikar PP, Patil SM, Patil BS, Reddy RC, Bagoji I, Kotennavar MS, Patil S, Patil AV, Das KK, Das SN, Bagali S. Effect of Mucuna pruriens on brain NMDA receptor and tau protein gene expression in cerebral ischemic rats. Front Physiol 2023; 14:1092032. [PMID: 36875022 PMCID: PMC9978338 DOI: 10.3389/fphys.2023.1092032] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Accepted: 02/06/2023] [Indexed: 02/18/2023] Open
Abstract
Present study aimed to assess effect of pre-treatment with Mucuna pruriens seed extract and its bioactive molecule(s) on NMDAR and Tau protein gene expression in cerebral ischemic rodent model. Methanol extract of M. pruriens seeds was characterized by HPLC, and β-sitosterol was isolated by flash chromatography. In vivo studies to observe the effect of pre-treatment (28 days) with methanol extract of M. pruriens seed and β-sitosterol on the unilateral cerebral ischemic rat model. Cerebral ischemia induced by left common carotid artery occlusion (LCCAO) for 75 min (on day 29) followed by reperfusion for 12 h. Rats (n = 48) divided into four groups. GroupI (control,Untreated + LCCAO)-No pre-treatment + cerebral ischemia; GroupII(β-sitosterol + Sham)-pre-treatment with β-sitosterol, 10 mg/kg/day + sham-operated; GroupIII(β-sitosterol + LCCAO)-pre-treatment with β-sitosterol, 10 mg/kg/day + cerebral ischemia; GroupIV(methanol extract + LCCAO)-pre-treatment with methanol extract of M. pruriens seeds, 50 mg/kg/day + cerebral ischemia. Neurological deficit score was assessed just before sacrifice. Experimental animals were sacrificed after 12 h reperfusion. Brain histopathology was performed. Gene expression of NMDAR and Tau protein of left cerebral hemisphere (occluded side) was performed by RT-PCR. Results revealed that the neurological deficit score was lower in groups III and IV compared to group I. NMDAR and tau protein mRNA expression in left cerebral hemisphere were upregulated in Group I, downregulated in groups III and IV. Histopathology of left cerebral hemisphere (occluded side) in Group I showed features of ischemic brain damage. Groups III and IV, left cerebral hemisphere showed less ischemic damage compared GroupI. Right cerebral hemisphere showed no areas of ischemia-induced brain changes. Pre-treatment with β-sitosterol and methanol extract of M. pruriens seeds may reduce ischemic brain injury following unilateral common carotid artery occlusion in rats.
Collapse
Affiliation(s)
- Prachi P Parvatikar
- Laboratory of Vascular Physiology and Medicine, Department of Physiology, Shri B. M. Patil Medical College, Hospital & Research Centre, BLDE (Deemed to be University), Vijayapura, Karnataka, India
| | - S M Patil
- Laboratory of Vascular Physiology and Medicine, Department of Physiology, Shri B. M. Patil Medical College, Hospital & Research Centre, BLDE (Deemed to be University), Vijayapura, Karnataka, India
| | - Bheemshetty S Patil
- Department of Anatomy, Shri B. M. Patil Medical College, Hospital & Research Center, BLDE (Deemed to be University), Vijayapura, Karnataka, India
| | - R Chandramouli Reddy
- Department of Biochemistry, Shri B. M. Patil Medical College, Hospital & Research Center, BLDE (Deemed to be University), Vijayapura, Karnataka, India
| | - Ishwar Bagoji
- Department of Anatomy, Shri B. M. Patil Medical College, Hospital & Research Center, BLDE (Deemed to be University), Vijayapura, Karnataka, India
| | - Manjunath S Kotennavar
- Department of Surgery, Shri B. M. Patil Medical College, Hospital & Research Center, BLDE (Deemed to be University), Vijayapura, Karnataka, India
| | - Sumangala Patil
- Laboratory of Vascular Physiology and Medicine, Department of Physiology, Shri B. M. Patil Medical College, Hospital & Research Centre, BLDE (Deemed to be University), Vijayapura, Karnataka, India
| | - Aravind V Patil
- Department of Surgery, Shri B. M. Patil Medical College, Hospital & Research Center, BLDE (Deemed to be University), Vijayapura, Karnataka, India
| | - Kusal K Das
- Laboratory of Vascular Physiology and Medicine, Department of Physiology, Shri B. M. Patil Medical College, Hospital & Research Centre, BLDE (Deemed to be University), Vijayapura, Karnataka, India
| | - Swastika N Das
- Department of Chemistry, BLDEA's V P Dr PG Halakatti College of Engineering and Technology, Vijayapura, Karnataka, India
| | - Shrilaxmi Bagali
- Laboratory of Vascular Physiology and Medicine, Department of Physiology, Shri B. M. Patil Medical College, Hospital & Research Centre, BLDE (Deemed to be University), Vijayapura, Karnataka, India
| |
Collapse
|
4
|
Khanaki K, Abedinzade M, Daei S. Effects of Urtica dioica extract on caspase-3 and cyclooxygenase-2 genes expression in a rat stroke model. GENE REPORTS 2022. [DOI: 10.1016/j.genrep.2022.101697] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
5
|
Zhang J, Jiang M, Zhao H, Han L, Jin Y, Chen W, Wang J, Zhang Z, Peng C. Synthesis of Paeonol-Ozagrel Conjugate: Structure Characterization and In Vivo Anti-Ischemic Stroke potential. Front Pharmacol 2021; 11:608221. [PMID: 33597878 PMCID: PMC7883289 DOI: 10.3389/fphar.2020.608221] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2020] [Accepted: 12/11/2020] [Indexed: 12/16/2022] Open
Abstract
Ischemic stroke is a common neurological disease that can lead to mortality and disability. The current curative effect remains unsatisfactory because drug accumulation in the diseased areas is insufficient as a result of the unique blood–brain barrier. Therefore, much attention has been paid to develop a novel therapeutic compound, paeonol-ozagrel conjugate (POC), for ischemic stroke. Then, POC was successfully synthesized by conjugating of paeonol and ozagrel as mutual prodrug. A series of in vitro characterizations and evaluations, including high - resolution mass spectroscopy, nuclear magnetic resonance spectroscopy, partition coefficient, and assessment of cytotoxicity against PC12 cells, were performed. Pharmacokinetic study demonstrated POC is eliminated quickly (t1/2 = 53.46 ± 19.64 min), which supported a short dosing interval. The neurological score, infarct volume, histopathological changes, oxidative stress, inflammatory cytokines levels, and TXA2 levels also were evaluated in vivo in middle cerebral artery occlusion (MCAO) rats. All results showed that POC had a significant curative and therapeutic effect on ischemic stroke, as evaluated by the middle cerebral artery occlusion. Overall, POC can be expected to become a new drug candidate for the treatment of ischemic stroke.
Collapse
Affiliation(s)
- Jing Zhang
- College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.,Institute of Pharmaceutics, Anhui Academy of Chinese Medicine, Hefei, China.,Anhui Province Key Laboratory of Pharmaceutical Preparation Technology and Application, Hefei, China
| | - Miaomiao Jiang
- College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.,Institute of Pharmaceutics, Anhui Academy of Chinese Medicine, Hefei, China.,Department of Pharmacy, the Fourth Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Hui Zhao
- Department of Pharmacy, the Fourth Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Lan Han
- College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.,Institute of Pharmaceutics, Anhui Academy of Chinese Medicine, Hefei, China.,Anhui Province Key Laboratory of Pharmaceutical Preparation Technology and Application, Hefei, China
| | - Yu Jin
- Chaohu Jinchen Pharmacy Co., Ltd., Shanghai Haihong Industrial Group, Chaohu, China
| | - Weidong Chen
- College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.,Institute of Pharmaceutics, Anhui Academy of Chinese Medicine, Hefei, China.,Anhui Province Key Laboratory of Pharmaceutical Preparation Technology and Application, Hefei, China
| | - Jianqing Wang
- Department of Pharmacy, the Fourth Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Ziyu Zhang
- College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.,Institute of Pharmaceutics, Anhui Academy of Chinese Medicine, Hefei, China
| | - Can Peng
- College of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.,Institute of Pharmaceutics, Anhui Academy of Chinese Medicine, Hefei, China.,Anhui Province Key Laboratory of Pharmaceutical Preparation Technology and Application, Hefei, China
| |
Collapse
|